Boston Scientific Corporation
BSX
$103.29
-$1.51-1.44%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.66B | 4.56B | 4.21B | 4.12B | 3.86B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.66B | 4.56B | 4.21B | 4.12B | 3.86B |
| Cost of Revenue | 1.47B | 1.48B | 1.32B | 1.28B | 1.22B |
| Gross Profit | 3.20B | 3.09B | 2.89B | 2.84B | 2.64B |
| SG&A Expenses | 1.60B | 1.61B | 1.56B | 1.45B | 1.36B |
| Depreciation & Amortization | 219.00M | 225.00M | 205.00M | 213.00M | 214.00M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.73B | 3.77B | 3.49B | 3.32B | 3.16B |
| Operating Income | 937.00M | 790.00M | 718.00M | 799.00M | 693.00M |
| Income Before Tax | 805.00M | 585.00M | 669.00M | 420.00M | 609.00M |
| Income Tax Expenses | 133.00M | 23.00M | 200.00M | 98.00M | 115.00M |
| Earnings from Continuing Operations | 672.00M | 562.00M | 469.00M | 322.00M | 494.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 2.00M | 4.00M | -- | 2.00M | 1.00M |
| Net Income | 674.00M | 566.00M | 469.00M | 324.00M | 495.00M |
| EBIT | 937.00M | 790.00M | 718.00M | 799.00M | 693.00M |
| EBITDA | 1.26B | 1.14B | 1.02B | 1.11B | 997.00M |
| EPS Basic | 0.46 | 0.38 | 0.32 | 0.22 | 0.34 |
| Normalized Basic EPS | 0.35 | 0.32 | 0.28 | 0.31 | 0.26 |
| EPS Diluted | 0.45 | 0.38 | 0.32 | 0.22 | 0.33 |
| Normalized Diluted EPS | 0.35 | 0.32 | 0.27 | 0.31 | 0.26 |
| Average Basic Shares Outstanding | 1.48B | 1.47B | 1.47B | 1.47B | 1.47B |
| Average Diluted Shares Outstanding | 1.49B | 1.49B | 1.49B | 1.48B | 1.48B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |